Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Novacyt

Biotech & Life Sciences · Vélizy-Villacoublay, France · Founded 2006 · IPO 2012 Thoroughbred

Oncology and infectious disease diagnostic products

Valuation
$9.7M
Market cap · May/2026
Revenue
$23M
Latest reported FY

Global footprint

Where Novacyt has talent and traffic

Workforce by country
4 countries with
team presence
🇬🇧 United Kingdom88.2%
🇨🇱 Chile5.9%
🇮🇳 India3%
🇫🇷 France3%
4 countries shown
Web traffic by country
10K monthly visits
across markets
🇬🇧 United Kingdom78%
🇫🇷 France20%
🇳🇱 Netherlands5%
Top 3 markets shown

Capital deployed

Novacyt's 3 investments and acquisitions.

Every disclosed deal where Novacyt appeared as a backer or acquirer, 2014–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Novacyt's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Novacyt's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Novacyt

        An AI-synthesized read of the highest-engagement posts about Novacyt on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Novacyt on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.